Linked Life Data

17636603

Source:http://linkedlifedata.com/resource/pubmed/id/17636603

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17636603rdf:typepubmed:Citationlld:pubmed
pubmed-article:17636603lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C0002844lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C0403823lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C0028953lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C0424092lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C1696465lld:lifeskim
pubmed-article:17636603lifeskim:mentionsumls-concept:C0332240lld:lifeskim
pubmed-article:17636603pubmed:issue4lld:pubmed
pubmed-article:17636603pubmed:dateCreated2007-7-19lld:pubmed
pubmed-article:17636603pubmed:abstractTextOligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility. Androgens have been suggested as a treatment because its binding proteins maintain a maintain a high intratesticular level testosterone essential for spermatogenesis and because the epididymis and seminal vesicles affect the seminal constitution and sperm motility and are also androgen-dependent. However exogenous testosterone was found to exert negative feedback on the pituitary-gonadal axis and thereby to suppress FSH and LH secretion. Spermatogenesis was thus adversely affected. Nevertheless androgens are used for the treatment of male infertility either for a putative direct "stimulatory" or "rebound" therapy. The stimulatory androgens used are mesterolone and testosterone undecanoate which, it is postulated, in a form and dosage that does not influence pituitary gonadotrophin secretion, either have a direct stimulatory effect on spermatogenesis or influence sperm transport and maturation though an effect on the epididymis, ductus deferens and seminal vesicles. Other androgens have been used to produce a rebound effect. These androgens are administered to suppress gonadotrophin secretion and spermatogenesis. After androgen therapy is discontinued there is a surge of FSH and LH and spermatogenesis is recommenced. Because of their different proposed mechanisms of action, stimulatory and rebound androgen therapy are analysed separately in the comparisons. This review considers the available evidence of the effect of androgens for idiopathic oligo and/or asthenospermia.lld:pubmed
pubmed-article:17636603pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17636603pubmed:languageenglld:pubmed
pubmed-article:17636603pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17636603pubmed:citationSubsetIMlld:pubmed
pubmed-article:17636603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17636603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17636603pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17636603pubmed:statusMEDLINElld:pubmed
pubmed-article:17636603pubmed:issn1469-493Xlld:pubmed
pubmed-article:17636603pubmed:authorpubmed-author:HughesEElld:pubmed
pubmed-article:17636603pubmed:authorpubmed-author:VailAAlld:pubmed
pubmed-article:17636603pubmed:authorpubmed-author:LilfordRRlld:pubmed
pubmed-article:17636603pubmed:authorpubmed-author:Vandekerckhov...lld:pubmed
pubmed-article:17636603pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17636603pubmed:ownerNLMlld:pubmed
pubmed-article:17636603pubmed:authorsCompleteYlld:pubmed
pubmed-article:17636603pubmed:paginationCD000150lld:pubmed
pubmed-article:17636603pubmed:dateRevised2009-11-3lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:meshHeadingpubmed-meshheading:17636603...lld:pubmed
pubmed-article:17636603pubmed:year1996lld:pubmed
pubmed-article:17636603pubmed:articleTitleWITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.lld:pubmed
pubmed-article:17636603pubmed:affiliationSt Mary's Hospital, IOW Healthcare NHS Trust, Parkhurst Road, Newport, Isle of Wight, UK, PO30 5TG. Patrick.Vandekerckhove@iow.nhs.uklld:pubmed
pubmed-article:17636603pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17636603pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17636603lld:pubmed